Aethlon Medical (NASDAQ:AEMD) Raised to Sell at StockNews.com

Aethlon Medical (NASDAQ:AEMD) was upgraded by equities researchers at StockNews.com to a “sell” rating in a research report issued on Wednesday.

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Aethlon Medical in a research note on Thursday, January 30th.

Aethlon Medical Price Performance

Shares of NASDAQ:AEMD opened at $0.64 on Wednesday. The business’s 50-day moving average is $0.64 and its 200 day moving average is $0.48. Aethlon Medical has a 1 year low of $0.24 and a 1 year high of $1.85. The firm has a market capitalization of $9.25 million, a P/E ratio of -0.23 and a beta of 1.88.

Aethlon Medical (NASDAQ:AEMD) last issued its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09. On average, analysts expect that Aethlon Medical will post -1.01 EPS for the current year.

Hedge Funds Weigh In On Aethlon Medical

Hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC purchased a new position in Aethlon Medical during the fourth quarter worth approximately $25,000. Allegiance Financial Group Advisory Services LLC purchased a new position in shares of Aethlon Medical in the fourth quarter valued at approximately $26,000. Sassicaia Capital Advisers LLC purchased a new position in shares of Aethlon Medical in the fourth quarter valued at approximately $31,000. Virtu Financial LLC purchased a new position in shares of Aethlon Medical in the fourth quarter valued at approximately $81,000. Finally, Boothbay Fund Management LLC purchased a new position in shares of Aethlon Medical in the fourth quarter valued at approximately $186,000. Hedge funds and other institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.